In MCF-7 cells, 24 h RITA treatment at 0.5–5 µM increased p53 and cleaved PARP1 but did not reproduce nutlin-3a-mediated PARP1 protein reduction. MDM2 mRNA increased. Thus, p53 accumulation alone did not predict PARP1 depletion in this model. [4]
Radiolabeled RITA binding to the human p53 N-terminal fragment
Biochemical assay · Purified GST–human p53 N-terminus (residues 2–65), GST-tag control, human fibrinogen and human serum albumin [1]
[14C]-RITA formed a shifted complex with GST–Np53 and HSA, but not fibrinogen; GST alone showed weak interaction. Standard denaturation disrupted the complexes. These assays support association with a p53 fragment but do not alone establish inhibition of cellular p53–MDM2 binding.
Literature-Reported Treatment Conditions
- Treatment concentration
- 40 µM [14C]-RITA with 20 µM purified protein (2:1 molar ratio)
- Exposure duration
- 30 min
- Method
- Incubation at 37°C followed by non-denaturing band-shift analysis; standard denaturation as a reversibility control.
- Reported limits
- Vehicle fraction and assay replicate count for Figure 1C–D are not specified in the inspected main-text methods/caption.
Methods and source locations
Compound reported in the paper: RITA (NSC 652287)
Evidence concerns the tested research material; it does not validate a current Adooq lot or establish clinical efficacy.
Figures 1C–D and 2B; Results, RITA Interacts With the N-Terminus of p53; Methods, Binding Assays With [14C]-RITA
Association with GST–Np53 versus protein controls: Autoradiography with Coomassie protein visualization — Figures 1C and 2B; N-terminal binding Results
Persistence of RITA/protein complexes under denaturing conditions: Band-shift assay under standard denaturing conditions — Figure 1D and corresponding Results
Recombinant SULT1A1 activity in the presence of RITA
Biochemical assay · Recombinant human SULT1A1 with sulfate donor PAPS [3]
A phosphatase-coupled assay detected increasing enzyme activity with increasing SULT1A1 in the presence of fixed RITA. This supports RITA serving as a sulfotransferase substrate; the readout does not directly identify a reactive metabolite or establish the sole cellular target.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2.5 µM RITA (Figure 2f); 0.2 mM PAPS (Methods)
- Exposure duration
- 1 h
- Method
- 37°C incubation; phosphatase-coupled Universal Sulfotransferase Activity Kit; absorbance detection at 620 nm.
- Vehicle
- RITA stock dissolved in DMSO; final assay DMSO fraction not specified.
- Reported limits
- Supplementary Figure 4g was not read. No kinetic constant or metabolite structure is extracted.
Methods and source locations
Compound reported in the paper: RITA (NSC 652287)
Evidence concerns the tested research material; it does not validate a current Adooq lot or establish clinical efficacy.
Figure 2f; Results, Metabolic mechanisms of small-molecule activation; Methods, SULT1A1 and BLVRB kinetic assays; Small molecules for validation assays
Sulfotransferase activity in the presence of fixed RITA: Phosphatase-coupled assay, ΔOD620 — Figure 2f and caption; kinetic assay Methods
RITA did not disrupt p53–HDM2 association in a cellular co-immunoprecipitation assay
Cell-based study · p53+/+ HCT116 human colorectal carcinoma cells [2]
RITA did not disrupt the p53–HDM2 interaction under the tested conditions, whereas nutlin-3 served as a disrupting comparator. This is a condition-specific negative result relevant to interpretation of RITA as a p53-pathway reagent.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM RITA; 4 µM nutlin-3 comparator; 10 µM MG132 in all compared conditions
- Exposure duration
- 16 h
- Method
- Anti-p53 DO-1 immunoprecipitation followed by immunoblotting for associated HDM2 and total precipitated p53; whole-cell extracts assessed.
- Vehicle
- DMSO control
- Co-treatment
- MG132 (10 µM) was present during RITA, nutlin-3 and control treatments; nutlin-3 was a separate comparator, not combined with RITA.
- Reported limits
- No replicate count or quantitative inhibition estimate supplied for Figure 6A in the inspected caption.
Methods and source locations
Compound reported in the paper: RITA (NSC 652287)
Evidence concerns the tested research material; it does not validate a current Adooq lot or establish clinical efficacy.
Figure 6A; Results, RITA does not disrupt the p53-HDM2 interaction; Methods, Inductions and drug treatments and Western blot analysis and immunoprecipitation
HDM2 associated with immunoprecipitated p53: Co-immunoprecipitation and immunoblotting — Figure 6A and corresponding Results
RITA stabilized p53 without reproducing nutlin-3a-mediated PARP1 reduction
Cell-based study · MCF-7 human breast cancer cells [4]
RITA increased p53 and cleaved PARP1, but did not reproduce the reduction in PARP1 protein seen with nutlin-3a. MDM2 mRNA increased after RITA. The negative PARP1 result prevents equating p53 accumulation with PARP1 depletion.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5, 1 and 5 µM RITA; 0 µM control; separate 10 µM nutlin-3a comparator
- Exposure duration
- 24 h
- Method
- Immunoblotting for p53 and PARP1 with GAPDH loading control; MDM2 qRT-PCR normalized to β-ACTIN.
- Vehicle
- Reagents dissolved in DMSO; final treatment DMSO fraction not specified.
- Reported limits
- Figure 2A blot replicate count is not separately specified; n = 3 different experiments applies to qRT-PCR panels B–C in the caption.
Methods and source locations
Compound reported in the paper: RITA (NSC 652287)
Evidence concerns the tested research material; it does not validate a current Adooq lot or establish clinical efficacy.
Figure 2A–C; Results, MDM2 is required for nutlin-3a-mediated reduction of PARP1 protein; Methods, Cell culture and reagents, immunoblotting and qRT-PCR
p53 stabilization and PARP1 protein response: Immunoblotting, GAPDH loading control — Figure 2A and corresponding Results
MDM2 transcript response: qRT-PCR normalized to β-ACTIN — Figure 2B and caption